A 68-year-old man who was admitted to our hospital because of general fatigue and anorexia. He was diagnosed as suffering from neuron specific enolase (NSE)-producing IgD-lambda type multiple myeloma with high activity of serum amylase, based on the detection of monoclonal IgD-lambda M-protein in the serum and urine, markedly high activities of salivary-type amylase and NSE in the serum, and immunohistochemical evidence of NSE and IgD in the myeloma cells. After two courses of alpha-IFN and VMCP chemotherapy, serum IgD, amylase and NSE decreased to normal levels. These observations indicate that NSE was ectopically produced by myeloma cells.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study.
Hemasphere
January 2025
Hematology Unit, AOU delle Marche Ancona Italy.
The definition of high-risk (HR) multiple myeloma (MM) is still a matter of debate. We prospectively evaluated the HR detection using FISH in combination with SKY92 gene expression profiling in 258 MM patients (newly diagnosed [ND] MM: = 109; relapsed/refractory [RR] MM: = 149). HR SKY92 was significantly enriched in RRMM (57/121, 47.
View Article and Find Full Text PDFMarkedly T2-Hypointense Clival Plasmacytoma With Light Chain Deposition Disease: A Case Report.
Cureus
December 2024
Department of Medical Imaging, University of Arizona College of Medicine - Tucson, Tucson, USA.
Plasmacytomas are rare monoclonal neoplastic plasma cell proliferations in soft tissue or bone, with clival plasmacytomas being extremely rare and occasionally presenting with light chain deposition disease (LCDD). While imaging findings for clival plasmacytomas have shown variable T2 signal characteristics, complete T2 signal loss has not been previously reported. We present a case of a 61-year-old female found to have a 1.
View Article and Find Full Text PDFIncome and education affect prognosis and treatment in symptomatic myeloma : A population-based study on 8672 multiple myeloma patients diagnosed 2008-2021 from the Swedish myeloma registry.
Ann Hematol
January 2025
Department of Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Despite advancements in multiple myeloma treatment, prognostic variability persists. We investigated the impact of income and education on treatment and survival in a country with publicly funded healthcare. We analysed data from the Swedish Myeloma Registry (2008-2021) linked to national registers.
View Article and Find Full Text PDFTotal marrow irradiation as part of autologous stem cell transplantation for patients with multiple myeloma.
Ann Hematol
January 2025
Department of Hematology, Kanghua Hospital, Dongguan, Guangdong, P.R. China.
The efficacy and safety of total marrow irradiation (TMI) plus a reduced dose of melphalan as autologous stem cell transplantation (ASCT) preconditioning for multiple myeloma (MM) patients were evaluated. The 11 patients with MM had a median age of 57 (range: 46-75) years; six of them were at standard risk and five of them were at high risk based on the Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART) standard risk factors. Before ASCT, three patients achieved stringent complete response (sCR), two patients achieved complete remission (CR), and the rest of the patients had either partial response (PR) or progressive disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!